ABT vs HCAT · P/E 25, rev $44.33B vs rev $141.2M
Abbott Laboratories (ABT) versus Health Catalyst Inc (HCAT) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Health Catalyst Inc (HCAT) is a health information services company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported HCAT revenue for 2026-06-30 was $141.2M. Net income was -$151.6M. Revenue was up 99.6% from 2026-03-31 to 2026-06-30. HCAT currently screens at market cap $130.8M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. HCAT currently screens at market cap $130.8M.
Not investment advice. Open the ABT and HCAT stock pages for the full models.
Not investment advice.